5 Tips from Venture Capitalists on Raising Capital for Your Biotech Startup


Research and development are vital for any biotech startup, however, raising venture capital (VC) can be a challenge for even the most experienced entrepreneurs. During November’s 2021 Biotech Start-Up Symposium, we were happy to have several VCs, industry leaders and experienced attorneys join us to provide key insights on what startup pioneers should know before pitching to a VC firm.

Tip 1: Know Thy Investor

Start by creating a potential roster of VCs that have a history of investing in the biotech space that you are part of. Pitching to a VC firm without sector experience in the biological arena is risky. Chances are they don’t know the ins and outs of getting a drug or device to market – let alone the science behind your idea. According to Dr. Anique ter Braake of M Ventures, the corporate strategic venture arm of

Merck KGaA, Darmstadt, Germany
“Institutional VC firms’ business is based on high risk high return promise of innovation in start-up companies. Strategic investors are not different, but more weight is put on strategic returns. With either mechanism, it is important to understand the field with all the risks and benefits that you will encounter along the way, which can be pretty lengthy in venture investing. Taking a biotech or tech startup from inception to  realization of their offering is not for the faint hearted.  These are long-term relationships – that many state akin to a marriage,” she said. Finding a VC firm that understands that concept is vitally important.

“These are long-term relationships – akin to a marriage.”

~Dr. Anique ter Braake, M Ventures

Tip 2: Put Yourself in the Shoes of the Investor

During the symposium, Matthew Meyer, Chief Business Advisor at the law firm Wilson Sonsini, said VC firms look at more than just your idea. He said, “Investors want to know why this opportunity? Why you? And why now?” Investors are more likely to trust their money with companies and individuals with deep domain expertise, a passion for solving problems and working in a big market.

Dr. ter Braake reminded attendees of the symposium that “as with many walks of life, you mostly will have only one chance to make a first impression.” So come up with a strong point plan and positioning strategy while also having a detailed plan for what your investor’s money will be used for if they choose to invest with you.

“Investors want to know why this opportunity? Why you? And why now?”

~Matthew Meyer, Wilson Sonsini

Tip 3: Don’t Oversell Your Idea

You love your idea and have spent countless hours making it a reality. But keep in mind that it’s easy to get caught up in the excitement and prospects of your own idea. Ms. ter Braake reminded attendees of the symposium that overselling your idea will set off alarm bells that you will not be able to un-ring.

She went on to say, “When VC firms hear statements like “We will see no side effects at all” or “There is no competition,” they are immediately skeptical. In most cases, VCs you meet have already done a quick analysis of the opportunity hence know more than what they may show at the meeting. Chances are that someone else has thought of something similar or another group of scientists are working to solve the problem in a different way. It’s important to be confident but stay factual. Investors want to know what is different about your idea, what problem it will solve, and why you are the best team to deliver that.

Tip 4: Communicate! Communicate! Communicate!

When looking outward for funding don’t forget to look inward at how your team is communicating with one another. Dr. Johnson reminded attendees that an effective intellectual property (IP) strategy means getting all team members on the same page. Ensure your entire team attends regularly scheduled meetings to discuss the latest developments and to make each department aware of what is going on elsewhere. Working in closed-off silos will lead to problems downstream. But regularly scheduled meetings between your R&D team, management, IP counsel and anyone else on your IP strategy team is key to VC success.

“An effective ongoing IP strategy should involve open communication.”

 ~Dr. Lee A. Johnson, Wilson Sonsini

Tip 5: Expect the Unexpected

You’ve done your research, scheduled a meeting with a potential investor and are about to pitch your idea. Suddenly, the electricity goes out in the conference room and the pitch deck you’ve spent so much time on can’t be shared on the big screen.

It sounds silly. But these things happen. Anyone who has attended a Zoom meeting recently knows that audio and visual issues are common. The best defense is to know your material cold. You and your team have to know your data like the back of your hand, so it can be shared no matter where you are or who you are with. Mr. Meyer said it best when he said “Remember that this is hard work. Try to embrace it.”

One Last Thing

Before finishing her session, Dr. ter Braake shared one last piece of advice for biotech pioneers: “Keep at it. Just because they said “no” the first time doesn’t mean they will the second or third time.”

“Keep at it. Just because they said “no” the first time

doesn’t mean they will the second or third time.”

~Dr. Anique ter Braake, M Ventures


Biotechnology Associate Analyst at M Ventures

Anique ter Braake, PhD, is Associate in the Biotechnology team. Anique joined M Ventures in February 2020 as analyst. Anique completed her PhD in the field of biomedicine, specifically focusing on chronic kidney disease induced cardiovascular complications. During her PhD, Anique studied mechanisms of vascular calcification and potential interventions in cellular and animal models. Anique obtained a Master’s degree at the VU University Amsterdam in biomedicine and fulfilled the extracurricular trajectory Science Based Business at Leiden University. Anique is based in Amsterdam at the M Ventures head office.

Matthew, is an experienced life science executive and corporate attorney who has held diverse roles across a wide range of private and public biopharma, MedTech, and precision medicine companies from start-ups to Fortune 50 in the U.S. and Europe. Matthew has led, structured and negotiated dozens of life science business development, joint venture and licensing transactions and has been instrumental in raising over $250 million for life science companies.

Lee provides counsel and assistance to clients in intellectual property matters, including patent counseling, drafting, and prosecution. Lee also represents clients in IP disputes before the courts and before the U.S. Patent and Trademark Office (USPTO), and he regularly acts on behalf of both investors and growth-stage innovative companies and transactional IP counsel in licensing and technology transfer matters, research collaborations and partnerships, initial public offerings (IPOs), mergers, and acquisitions. Lee represents clients from a range of industries, including biotechnology, pharmaceuticals, medical devices, and agriculture and food technologies.

Related Posts

Watch on Demand! Biolabs European expansion

BioLabs builds innovation communities around Biotech entrepreneurs providing them with infrastructure, support, and networking to successfully succeed. Hear...

Mirrored disco balls

Bridging the Sponsor – CMO Data Gulf

Single-source manufacture of biopharmaceuticals is becoming more and more rare. Increasingly, biomanufacturers or “sponsor” companies partner with contract…

Watch on Demand! The Current State of Emerging Biotech Venture Capital & How to Successfully Raise Funds

Insights on the changes in the biotech VC landscape and tips from an investor perspective for companies fundraising...

Strengthening the CDMO-Sponsor Partnership with Improved Data Sharing and Collaboration

Collaboration between biomanufacturers and CDMOs often experiences challenges with data sharing. This presentation highlights the management of heterogenous...

Good Laboratory Practice and the Impact on Start Up Companies

The definition of Good Laboratory Practice (GLP) is given by the Organization for Economic Co-operation and Development (OECD)…

Watch on Demand! Regulatory Considerations, Use of Ancillary Materials in Biologics Nov 14th, 2023

Understanding regulatory expectations for ancillary/raw materials during development and early clinical phases can be challenging. Join in for...

Scroll to Top